NCT04961658View on ClinicalTrials.gov

Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

August 10, 2023

Study Completion Date

January 8, 2024

Conditions
Septic Shock
Interventions
BIOLOGICAL

GEM00220

Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion

Trial Locations (4)

T5H 3V9

Royal Alexandra Hospital, Edmonton

L3P 7P3

Markham Stouffville Hospital - Oak Valley Health, Markham

L1G 2B9

Lakeridge Health, Oshawa

M5B 1W8

St. Michael's Hospital, Toronto

Sponsors
All Listed Sponsors
lead

Northern Therapeutics

INDUSTRY